Biotech
Vor Biopharma
Vor Biopharma raises $110M Series C at $700M valuation
$110M
Total Raised
Series C
Latest Round
2015
Founded
150+
Employees
200 Sidney Street, Cambridge, MA 02139
1 min read
Quick Facts
Valuation
$700M
Latest Round Size
$110M
Latest Round Date
August 2024
Vor Biopharma: Series C Funding Round
Vor Biopharma has successfully raised $110M in Series C funding, reaching a valuation of $700M.
Company Overview
Engineering hematopoietic stem cells
Funding Details
The Series C round was led by 5AM Ventures, with participation from Fidelity, SR One, Novartis Venture Fund, Cormorant Asset Management.
Company Information
- Headquarters: 200 Sidney Street, Cambridge, MA 02139
- Founded: 2015
- Employees: 150+
- Category: Biotech
Investment
Vor Biopharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- 5AM Ventures: Verified investor in Series C
- Fidelity: Verified investor in Series C
- SR One: Verified investor in Series C
- Novartis Venture Fund: Verified investor in Series C
- Cormorant Asset Management: Verified investor in Series C
Key Investors
5AM Ventures
Lead Investor
Verified investor in Series C
Fidelity
Investor
Verified investor in Series C
SR One
Investor
Verified investor in Series C
Novartis Venture Fund
Investor
Verified investor in Series C
Cormorant Asset Management
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M